Literature DB >> 9733485

Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6beta methyl, ethyl, and propyl analogues.

D J Drake1, R S Jensen, J Busch-Petersen, J K Kawakami, M Concepcion Fernandez-Garcia, P Fan, A Makriyannis, M A Tius.   

Abstract

The stereoelectronic requirements for interaction of the southern aliphatic hydroxyl of cannabimimetic pharmacophores with the CB1 and CB2 receptors are explored. The stereoselective syntheses of three series of classical/nonclassical hybrid cannabinoids are described. These compounds were designed to investigate the importance of the southern aliphatic hydroxyl (SAH) pharmacophore for cannabimimetic activity. Variation in the chain length of the SAH moiety in these 6beta-(hydroxyalkyl)dihydrobenzopyran analogues, from 6beta-hydroxymethyl to 6beta-(omega-hydroxyethyl) and 6beta-(omega-hydroxypropyl), and the effects of replacing the hydroxyl functionality by hydride and iodide are reported. Our results indicate that the SAH pharmacophore has less pronounced effects than the C-3 aliphatic chain on cannabinoid activity. Furthermore, it appears that this southern molecular component is capable of interacting with two different subsites on the receptor and that the nature of this interaction is determined by the terminal substituent on the C-6beta alkyl group. One of the subsites can accommodate the relatively polar SAH pharmacophore, while the second subsite interacts with more hydrophobic C-6beta substituents and can accommodate large spherical pharmacophores separated by three methylene carbons from the tricyclic cannabinoid template.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733485     DOI: 10.1021/jm960677q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Novel adamantyl cannabinoids as CB1 receptor probes.

Authors:  Ganesh A Thakur; Shama Bajaj; Carol Paronis; Yan Peng; Anna L Bowman; Lawrence S Barak; Marc G Caron; Demon Parrish; Jeffrey R Deschamps; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2013-05-14       Impact factor: 7.446

2.  Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand.

Authors:  R Lan; J Gatley; Q Lu; P Fan; S R Fernando; N D Volkow; R Pertwee; A Makriyannis
Journal:  AAPS PharmSci       Date:  1999

3.  Synthesis of (-)-Delta9-trans-tetrahydrocannabinol: stereocontrol via Mo-catalyzed asymmetric allylic alkylation reaction.

Authors:  Barry M Trost; Kalindi Dogra
Journal:  Org Lett       Date:  2007-02-01       Impact factor: 6.005

4.  Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues.

Authors:  Shashank Kulkarni; Spyros P Nikas; Rishi Sharma; Shan Jiang; Carol A Paronis; Michael Z Leonard; Bin Zhang; Chandrashekhar Honrao; Srikrishnan Mallipeddi; Jimit Girish Raghav; Othman Benchama; Torbjörn U C Järbe; Jack Bergman; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2016-07-13       Impact factor: 7.446

5.  C3-heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor.

Authors:  Darryl D Dixon; Marcus A Tius; Ganesh A Thakur; Han Zhou; Anna L Bowman; Vidyanand G Shukla; Yan Peng; Alexandros Makriyannis
Journal:  Bioorg Med Chem Lett       Date:  2012-06-15       Impact factor: 2.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.